support@mellalta.com   +1 (304) 306-0723

96.5% Adverse Events reported in mCRPC patients with Tecentriq + Xtandi Combination therapy

Researchers speculated that enzalutamide (Xtandi) could be a candidate for combination with anti-PD-1 or anti-PD-L1 agents such as Tecentriq (atezolizumab) as it “can improve IFNɣ signaling and sensitize cancer cells immune-mediated cell killing “. In […]

Read More

Get In Touch

Let's keep the conversation going